MaxCyte Bids Farewell to Longtime Board Member, Art Mandell
ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) —
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte’s growth and strategic direction. Upon Mr. Mandell’s retirement, MaxCyte will have nine directors.
Art Mandell, a longtime member of the Board of Directors of MaxCyte, has made significant contributions to the company since joining in 2006. His dedication, expertise, and strategic insights have played a key role in shaping MaxCyte’s growth and success in the field of cell engineering. As he bids farewell to his position, his presence will be deeply missed by the board and the company as a whole.
During his tenure, Art Mandell has been instrumental in guiding MaxCyte through various milestones and challenges, helping the company to establish itself as a leader in enabling platform technologies for cell therapeutics. His leadership and vision have been invaluable in shaping the strategic direction of the company and navigating the rapidly evolving landscape of biotechnology and healthcare.
As MaxCyte moves forward with a new composition of the Board of Directors, the company will continue to build on the foundation laid by Art Mandell and pursue its mission of advancing the discovery, development, and commercialization of next-generation cell therapies. His legacy will endure as a source of inspiration and guidance for the future endeavors of the company.
How will this affect me?
As a stakeholder in MaxCyte or someone interested in the field of cell engineering and therapeutics, the retirement of Art Mandell may have implications for the company’s future direction and strategic decision-making. His departure signifies a shift in leadership within the board and may influence the company’s approach to innovation and growth. It is important to stay informed about the changes within the company and how they may impact your involvement or interest in MaxCyte’s activities.
How will this affect the world?
The retirement of Art Mandell from the Board of Directors of MaxCyte represents a significant transition in the leadership of a company that plays a crucial role in advancing cell therapeutics and enabling technologies. His contributions to the field have had a global impact on healthcare and biotechnology, shaping the development of next-generation treatments and therapies. The changes within MaxCyte’s leadership may have ripple effects in the industry and influence the direction of research and innovation in cell engineering on a broader scale.
Conclusion
Art Mandell’s retirement from the Board of Directors of MaxCyte marks the end of an era for the company and signals a new chapter in its leadership and strategic direction. His legacy of dedication and expertise will continue to inspire and guide MaxCyte as it moves forward in its mission to advance the field of cell engineering and therapeutics. While his presence will be missed, the company is well-positioned to build on the foundation laid by Art Mandell and pursue new opportunities for growth and innovation in the future.
